Astellas, XenoPort Announce Results from Trial for Restless Legs Syndrome

Astellas Pharma Inc. and XenoPort, Inc. announced preliminary top-line results from a Phase 2 clinical trial of ASP8825/XP13512 for the treatment of symptoms in moderate-to-severe primary restless legs syndrome patients.
MarketWatch